Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2016 Publisher: Mercury Pharmaceuticals Ltd, Capital House, 85 King William Street, London, EC4N 7BL, UK
Felbinac is an anti-inflammatory/analgesic agent which has been developed into a topical gel for local treatment of pain and inflammation associated with conditions of the musculo-skeletal system.
This medicine administered in a pharmacokinetic study achieves similar low circulating levels of felbinac to this medicine.
Testing of biphenylacetic acid includes single and repeat dose studies, foetal toxicity and fertility studies, mutagenic and carcinogenic potential studies which show an acceptable toxicity profile for the active ingredient.
A primary dermal irritation study has shown this medicine to be non-irritant and that it can be safely applied to human skin.
This medicine is irritant to the eye but the irritation subsides within 7 days.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
